-
Recombinant SARS-CoV-2 Spike protein, Omicron variant, B.1.1.529, 21K clade
Recombinant SARS-CoV-2 Spike protein, Omicron variant, B.1.1.529, 21K clade
- 中文名称：
- Recombinant SARS-CoV-2 Spike protein, Omicron variant, B.1.1.529, 21K clade
- 英文名称：
- Recombinant SARS-CoV-2 Spike protein, Omicron variant, B.1.1.529, 21K clade
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA47148
- 规格：
- 0.1 mg|2x0.1 mg|3x0.1 mg|5x0.1 mg|4x0.1 mg
- 保存建议：
- The protein should be stored at -20°C to -70°C preferably in small aliquots to avoid repeated freeze-thaw cycles. Stability: At least 12 months at -20°C to -70°C and at least 1 month at 2°C to 8°C.
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- PBS 20% Glycerol
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel ?-CoV (1), named SARS- CoV-2, which started spreading very quickly causing a global pandemic COVID-19. Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer’s group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6).
On November 24, 2021, South Africa reported the identification of a new SARS-CoV-2 variant, B.1.1.529, to the World Health Organization (WHO). B.1.1.529 was first detected in specimens collected on November 11, 2021 in Botswana and on November 14, 2021 in South Africa. Omicron has many concerning spike protein substitutions, some of which are known from other variants to be associated with reduced susceptibility to available monoclonal antibody therapeutics or reduced neutralization by convalescent and vaccinee sera (7).
上一篇：Recombinant protein CysC (human)
下一篇：Recombinant SARS-CoV-2 Spike protein, Alpha Variant of Concern, B.1.1.7 variant (United Kingdom, HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H)
